Table 1.
Main characteristics of included studies.
| No. | First Author | Publication Year | Country | Study Design | N (Male/Female) | Control group | Age Mean ± SD or Medianor Median or range |
Sample source | Liquid biopsy biomarker | Detection Method | Main index |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chen | 2015 | China | cohort study | HCC:104(68/32) CHB:100(66/34) LC:90(58/32) hc:120(80/40) |
CHB/LC/ hc |
HCC:47.6(33,64) CHB:48.9(35,62) LC:46.1(36,60) hc:47.9(34,59) |
Serum | miR-96 | RT-PCR | sensitivity/specificity/AUC |
| 2 | Guo | 2021 | China | case control study | HCC:87 Gastric cancer:13 cholangiocarcinoma:15 hc:30 |
Gastric cancer/ cholangiocarcinoma/ hc |
N/A | plasma | Circular RNA 0006602 | qPCR | sensitivity/specificity/AUC |
| 3 | Yosry | 2022 | Egypt | observational cross-sectional study | Early Fibrosis:80(48/32) Advanced Liver Fibrosis:77(42/35) HCC:62(42/15) |
Early Fibrosis/ Advanced Liver Fibrosis |
Age: median Early Fibrosis:49(43,57) Advanced Liver Fibrosis:55(50,61) HCC:60(57,65) |
Serum | miR-141-3p/miR-155-5p/miR200a-3p miR-200c-3p, miR-/205-5p/miR-208a-3p, miR-499a-5p, miR-103a-3p, miR-574-3p and miR-15a-5p |
RT-PCR | sensitivity/specificity/cut -off/accuracy/AUROC/LR+/LR- |
| 4 | Hung | 2015 | China Taiwan | case control study | HCC: 120(96/24) DN: 30(24/6) hc:15(12/3) |
DN/hc | HCC: 58.5 ± 10.0 DN: 60.3 ± 11.1 hc:62.1 ± 8.7 |
serum | miR-122/let-7b | qRT-PCR | sensitivity/specificity/cut-off point/AUC |
| 5 | Gwad | 2018 | Egypt | case control study | HCC:60(43/17) CHC:42(33/9) hc:18(12/6) |
CHC/hc | ≥57.8;<57.8(numbers) HCC:35/25 CHC: 21/21 hc:9/9 |
serum | lncRNA‐RP11‐513I15.6/ miR‐1262/RAB11A mRNA |
qRT-PCR | sensitivity/specificity/ PPV/NPV/accuracy/cut off |
| 6 | Matboli | 2018 | Egypt | N/A | HCC:68(49/19) CHC:60(39/21) hc:36(23/13) |
CHC/ hc |
<56;≥56(numbers) HCC:23/45 CHC:28/32 hc:12/24 |
serum | hsa_circ_00156/ hsa_circ _000224/hsa_circ_000520 |
Real‐time PCR | sensitivity/specificity/ PPV/NPV/accuracy |
| 7 | Li | 2012 | China | case control study | HCC:101(76/25) CH and LC::30(23/7) hc:60(46/14) |
CH and LC/ hc |
HCC:54 ± 11 CH and LC:51 ± 13 hc:52 ± 16 |
serum | miR-18a | qPCR | sensitivity/specificity/cut-off point/AUC |
| 8 | Rashad | 2017 | Egypt | case control study | HCC: 51(31/20) LC: 39(18/21) |
LC | HCC:45.94 ± 6.42 LC: 48.28 ± 5.04 |
serum | miRNA-27a/ miRNA-18b |
qRT-PCR | sensitivity/specificity/cut-off point/AUC |
| 9 | Habib | 2019 | Egypt | case control study | HCC:65(46/19) CHC:34(27/7) hc:32(17/15) |
CHC/ hc |
≥56;<56(numbers) HCC:43/22 CHC: 22/12 hc: 15/17 |
serum | lncRNA-TSIX/miR-548-a-3p/SOGA1 mRNA | qPCR | sensitivity/specificity/cut-off point/AUC |
| 10 | EI-Hamouly | 2019 | Egypt | cross-sectional study | HCC:42(27/15) LC:48(29/19) hc:40(23/17) |
LC/ hc |
HCC:56.14 ± 8.67 LC:53.85 ± 6.37 hc:53.35 ± 5.71 |
Plasma | microRNA-301 | qRT-PCR | sensitivity/specificity/cut-off point/AUC |
| 11 | EIhendawy | 2020 | Egypt | cross section pilot study | HCC:20(11/9) hc:10(6/4) |
hc | HCC:54.93 ± 7.49 hc:51.72 ± 4.72 |
peripheral venous blood | miR-142-5p/miR-191-5p/miR-22-3p/miR-126-5p | RT-qPCR | sensitivity/specificity/ PPV/NPV/AUC |
| 12 | Piciocchi | 2013 | Italy | N/A | HCC:66(50/16) LC:35(21/14) CH:41(28/13) |
LC/ CH |
HCC:68.5 ± 9 LC:58 ± 13 CH:57 ± 12 |
Plasma | cfDNA | Real-time PCR | sensitivity/specificity/ PPV/NPV/AUC/accuracy/cut-off point |
| 13 | Yang | 2015 | China | case control study | HCC:156(111/45) BLD:98(CH:83, NAFLD:15) hc:64 |
BLD/ hc |
HCC: Mean age:53.7 | serum | miR-218 | qRT-PCR | sensitivity/specificity/cut-off point/AUC |
| 14 | Huang | 2011 | China | case control study | HCC:72 BLD:37,(LC:25, Chronic inactive CH:12)/ hc: 41 |
BLD:(LC, Chronic inactive CH)/ hc |
N/A | Plasma | circDNA | Real Time PCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off point |
| 15 | Chen | 2015 | China | case control study | HCC:103(89/14) BLD:95(80/15) hc:40(31/9) |
BLD: hc: |
Median (range) HCC:52(39-80) BLD:50(37-76) hc:49(30-78) |
Serum | miR-182/miR-331-3p | real-time PCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off point |
| 16 | Zuo | 2015 | China | N/A | HCC:90(68/22) CHB: 30(13/17) hc: 30(11/19) |
CHB, hc |
HCC:54.7 ± 9.8 CHB: 46.6 ± 15.4 hc: 51.8 ± 20.2 |
Serum | miR-125b/miR-223/miR-27a/miR26a | qRT-PCR | sensitivity/specificity/ AUC/cut-off point |
| 17 | Nasser | 2019 | Egypt | N/A | HCC:30(16/14) LC:15(11/4) CHC:15(9/6) hc: 25 |
LC/ CHC/ hc |
HCC:53.5 ± 4.9 LC:51 ± 5.7 CHC:32 ± 7.4 hc:N/A |
serum | miR-21/miR-223/miR-885-5p | (RT) PCR | sensitivity/specificity/ AUC/cut-off point |
| 18 | Fouda | 2020 | Egypt | case control study | HCC:137(93/44) hc:49 |
hc | HCC:61.1 ± 6.5 hc:60 ± 5.2 |
serum | miRNA21/miRNA29a/miRNA200/ miRNA335 |
qRT-PCR | sensitivity/specificity/ AUC/cut-off point/SEM |
| 19 | Li | 2019 | China | case control study | HCC:135 hc:103 CH:117 LC:143 |
hc/ CH/ LC |
N/A | plasma | circSMARCA5 | qRT-PCR | sensitivity/specificity/ AUC/cut-off |
| 20 | Abdelgawad | 2015 | Egypt | case control study | HCC:77(50/27) LC:30(19/11) hc:40(24/16) |
LC/ hc |
HCC:61(47-77) LC:58.5(55-64) hc:45-69 |
whole blood | KIAA0101 mRNA | qRT-PCR | sensitivity/specificity/ PPV/NPV/accuracy/ |
| 21 | Zhuang | 2015 | China | case control study | HCC:52(40/12) CH:42(27/15) HC:43(23/14) |
CH/ HC |
HCC:51.1 ± 1.4 CH:49.2 ± 1.8 HC:51.5 ± 2.1 |
serum | miR-21/miR-26a/miR-101 | qRT-PCR | sensitivity/specificity/ AUC |
| 22 | Lin | 2015 | China | Cohort | HCC:26(20/6) LC:22(16/6) CHB:23(16/7) hc:22(15/7) |
LC/ CHB/ hc |
HCC:49 ± 13 LC:51 ± 11 CHB:45 ± 11 hc:47 ± 12 |
Serum | miR-224 | qRT-PCR | sensitivity/specificity/ AUC |
| 23 | Han | 2018 | China | single centre, cohort study | HCC:155(127/28) LC:96(64/32) hc: 95(61/34) |
LC/ hc |
HCC:58.2 ± 10.5 LC: 52.4 ± 11.4 hc: 51.1 ± 13.7 |
plasma | miR-148a | qRT-PCR | sensitivity/specificity/ AUROC/cut-off point |
| 24 | Sun | 2019 | China | case control study | HCC:40(26/14) hc:45(26/19) Anhepatic fibrosis:13(8/5) Mild hepatic fibrosis:46(29/17) Severe liver fibrosis/LC:47(29/18) |
hc/ Anhepatic fibrosis/ Mild hepatic fibrosis/ Severe liver fibrosis/LC |
HCC:62.53 ± 9.92 hc:44.61 ± 14.95 Anhepatic fibrosis:36.79 ± 11.8 Mild hepatic fibrosis:45.1 ± 12.94 Severe liver fibrosis/LC:54.56 ± 7.75 |
Serum | miR-331-3p/miR-23b-3p | RT-qPCR | sensitivity/specificity/ AUC |
| 25 | Amr | 2017 | Egypt | case control study | HCC:40(33/7) CHC:40(34/6) hc:20(16/4) |
CHC/ hc |
HCC:52.03 ± 1.55 CHC:48.94 ± 1.34 hc:50.75 ± 1.8 |
plasma | miR-122/miR-224 | RT-quantitative PCR | sensitivity/specificity/ accuracy/cut-off point/AUC |
| 26 | Yang | 2017 | China | HCC:24(19/5) Fibrosis:62(46/16) |
Fibrosis | HCC:57.7 ± 8.7 Fibrosis:35.7 ± 10.1 |
plasma | cfDNA | Qubit dsDNA 7 HS Assay kit |
sensitivity/specificity/ PPV/NPV/cut-off point/AUC |
|
| 27 | Tomimaru | 2011 | Japan | case control study | HCC:126(99/27) CH:30(20/10) hc:50(37/13) |
CH/ hc |
HCC: 63 ± 10 CH:62 ± 8 hc:62 ± 8 |
Plasma | microRNA-21 | qRT-PCR | sensitivity/specificity/ AUC/accuracy |
| 28 | Shaheen | 2018 | Egypt | case control study | HCC:40(26/14) LC:20(15/5) CHC:20(13/7) hc:40(34/6) |
LC/ CHC/ hc |
HCC:58.0 ± 8.6 LC:57.2 ± 9.7 CHC:52.5 ± 9.04 hc:57.5 ± 10.0 |
Serum | miR-182/miR-150 | qRT-PCR | sensitivity/specificity/cut-off point/AUC |
| 29 | Luo | 2018 | China | case-control study | HCC:60(50/10) CHB and LC:75(59/16) hc:79(60/19) |
CHB and LC/ hc |
N/A | Plasma | ZFAS1 | RT-qPCR | sensitivity/specificity/cut-off point/AUC |
| 30 | Li | 2021 | China | case control study | HCC:116(62/54) CHB:66(35/31) hc:66(33/33) |
CHB/ hc |
HCC:56.12 ± 5.46 CHB:57.81 ± 5.69 hc:56.88 ± 6.23 |
serum | miR-487b | qRT-PCR | sensitivity/specificity/cut-off point/AUC |
| 31 | ALrefai | 2023 | Saudi Arabia | case control study | HCC:50(41/9) LC:50(38/12) hc:50(35/15) |
LC/ hc |
HCC:59.74± 6.16 LC: 57.68± 4.77 hc: 58.78± 4.03 |
blood | miR-331-3P/miR-23b-3p/miR-3194-5p | RT-PCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off point |
| 32 | Zhao | 2021 | China | case control study | HBV-unrelated HCC:52 CHB-related HCC:96 CHB:72 hc:76 |
CHB/ hc |
HBV-unrelated HCC:52(43-62) CHB-related HCC:55(41-67) CHB:50(38-61) hc:53(42-59) |
serum | miR-324-3p | qRT-PCR | sensitivity/specificity/cut-off point/AUC |
| 33 | Chen | 2016 | China | case control study | HCC:64(53/11) LC:59(44/15) CHB:63(51/12) hc:56(39/17) |
LC/ CHB/ hc |
HCC:54.00 ± 11.48 LC:52.93 ± 11.37 CHB:53.62 ± 11.04 hc:53.07 ± 11.83 |
Plasma | miR-125b | qRT-PCR | sensitivity/specificity/AUC |
| 34 | Huang | 2020 | China | case control study | HCC:129(111/18) hc:93(69/24) CHB:27(21/6) LC:49(32/17) |
hc/ CHB/ LC |
HCC:59(23-88) hc:55(21-79) CHB:52(33-71) LC:58(35-87) |
Serum | HULC/MALAT1/Linc00152/PTENP1/PTTG3P/SPRY4-IT1/UBE2CP3/UCA1 | qRT-PCR | sensitivity/specificity/AUC |
| 35 | Miura | 2005 | Japan | N/A | HCC:64 LC:20 CH:20 hc:50 |
LC/ CH/ hc |
N/A | Serum | hTERT mRNA | qRT-PCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off point |
| 36 | Shen | 2017 | China | case control study | HCC:70(46/24) LC:40(24/16) hc:45 |
LC/ hc |
HCC:mean:35(42-72) LC:48(37-69) hc:49(40-68) |
Serum | miR-574-3p | RT-qPCR | sensitivity/specificity/ PPV/NPV/AUC/accuracy |
| 37 | Nguyen | 2022 | Viet Nam | cross-sectional study | HCC:170(136/34) LC:170(90/80) |
LC | HCC:59.8 ± 11.3 LC:46.5 ± 13.8 |
Serum | hTERT mRNA | RT-PCR | sensitivity/specificity/AUC/cut-off |
| 38 | Miura | 2010 | Japan | case control study | HCC:303(196/107) CH:89 LC:45 hc:201 |
CH/ LC/ hc/ |
HCC:mean:65;range(22-101) | Serum | hTERTmRNA | RT-qPCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off |
| 39 | Zhang | 2014 | China | case control study | HCC:95(60/35) CH:118(65/33) hc:127(71/56) |
CH/ hc |
HCC:54.21 ± 6.95 CH:53.12 ± 7.24 hc:52.58 ± 6.98 |
Serum | microRNA 143/microRNA 215 | RT-qPCR | sensitivity/specificity/ AUC/cut-off/accuracy |
| 40 | Han | 2022 | China | case control study | HCC:127(81/46) hc:99(48/51) BLD:55(30/25) |
hc/ BLD |
HCC:56(45-65) hc:53(42-59) BLD:50(39-59) |
Serum | long non-coding RNA SCARNA10 | qPCR | sensitivity/specificity/AUC |
| 41 | Yu | 2015 | China | N/A | HCC: 120(75/45) CHB:110(67/43) hc: 120(65/55) |
CHB/ hc |
HCC:58 ± 10.4 CHB: 55 ± 11.2 hc:50 ± 9.5 |
Serum | microRNA-150 | qRT-PCR | sensitivity/specificity/ AUC/cut-off |
| 42 | Dhayat | 2015 | Germany | case control study | HCC: 22(20/2) LC: 22(13/9) hc: 15(7/8) |
LC/ hc |
N/A | plasma | microRNA-141/microRNA-200a | qRT-PCR | sensitivity/specificity/AUC/accuracy |
| 43 | Li | 2019 | China | N/A | HCC:47(31/16) hc: 54(23/31) CH: 54(31/23) LC: 35(22/13) |
hc/ CH/ LC |
HCC:63 ± 10 hc:45 ± 15 CH:37 ± 12 LC:55 ± 8 |
Serum | GPC3/miR-122 | qRT-PCR | sensitivity/specificity/ AUC/Cut-off |
| 44 | Gharib | 2022 | Saudi Arabia | case control study | HCC:55(33/22) LC:55(31/24) hc:55(37/18) |
LC/ hc |
HCC:54.83 ± 6.54 LC:54.91 ± 8.69 hc:55.40 ± 7.24 |
Serum | miRNA-96-5p/miRNA-99a-5p | qRT-PCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off/accuracy |
| 45 | Qiao | 2019 | China | N/A | HCC:100 CHB:50 hc:50 |
CHB/ hc |
N/A | plasma | Hsa_circ_0003998 | qRT-PCR | sensitivity/specificity/AUC |
| 46 | Quoc | 2018 | Vietnam | case control study | HCC: 25(17/8) CHB: 8(3/5) hc:19(13/6) |
CHB/ hc |
HCC: 51.28 ± 16.03 CHB: 41.13 ± 12.92 hc:55.79 ± 7.8 |
plasma | hsa-miR122 | RT-PCR | sensitivity/specificity/AUC |
| 47 | Wang | 2018 | China | N/A | HCC: 63(54/9) CHB: 46(34/12) LC: 47(39/8) hc:58(49/9) |
CHB/ LC/ hc |
HCC:56 ± 9 CHB:54 ± 12 LC:55 ± 10 hc:55 ± 10 |
plasma | lncRNA GAS5-AS1 | RT-qPCR | sensitivity/specificity/ AUC/Cut-off |
| 48 | Wang | 2023 | China | N/A | HCC:98(60/38) LC:52(28/24) hc:105(62/43) |
LC/ hc |
HCC: 56.3 ± 9.76 LC:57.98 ± 11.35 hc:54.8 ± 15.05 |
plasma | Lnc-MyD88 | RT-qPCR | sensitivity/specificity/ AUC/Cut-off/Jorden index |
| 49 | Yousuf | 2022 | India | N/A | HCC:33(22/11) hc:33(23/10) |
hc | HCC:56.58 ± 12.29 hc:51.68 ± 15.09 |
Serum | miR-221/miR-222/miR-26a/miR-124/miR-340/miR-126/miR-155miR-219 | RT-qPCR | sensitivity/specificity/ AUC/Cut-off |
| 50 | Elfert | 2022 | Egypt | case control study | HCC:90(72/18) CHC:90(66/24) hc:60(35/25) |
CHC/ hc |
HCC: 47.43 ± 7.56 CHC: 43.40 ± 11.66 hc: 44.0 ± 7.32 |
Serum | miR-122/miR-483/miR-335 | qRT-PCR | sensitivity/specificity/ AUC/Cut-off |
| 51 | Eldosoky | 2023 | Egypt | N/A | HCC:39(27/12) LC: 40(28/12) |
LC | HCC: 61.0 (56.0–67.0) LC:58.5 (54.25–65.0) |
plasma | hsa-miR-21-5p/hsa-miR-155-5p/hsa-miR-199a-5p | qRT-PCR | sensitivity/specificity/ AUC/Cut-off |
| 52 | Boonkaew | 2023 | Thailand | N/A | HCC:70(54/16) NAFLD:70(30/40) hc:35(4/31) |
NAFLD/ hc |
HCC:68.8 ± 11.4 NAFLD:50.7 ± 9.5 hc:53.2 ± 5.3 |
plasma | miR-19-3p/miR-16-5p/miR-30d-5p/ | qRT-PCR | sensitivity/specificity/ PPV/NPV/AUROC/cut-off/accuracy |
| 53 | Gao | 2018 | China | N/A | HCC:72(57/15) CH: 50(39/11) hc:50(35/15) |
CH/ hc |
HCC:51.26 ± 7.31 CH:49.23 ± 8.06 hc:50.37 ± 7.19 |
plasma | SHNG1 | N/A | sensitivity/specificity/ AUC |
| 54 | Zhao | 2018 | China | N/A | HCC:85 (60/25) CHB:50 |
CHB | HCC:53.2 ± 9.3 | Serum | microRNA-143/145 | RT-qPCR | sensitivity/specificity/ AUC |
| 55 | Li | 2014 | China | N/A | HCC:31(26/5) CH:31(26/5) |
CH | HCC:49 ± 11 CH:49 ± 10 |
plasma | microRNA-139 | RT-qPCR | sensitivity/specificity/ AUC/Cut-off |
| 56 | Xie | 2014 | China | N/A | CHB:79(54/25) LC:61(43/18) HCC:67(57/10) hc:30(21/9) |
CHB/ LC/ hc |
CHB:32.38 ± 11.93 LC:51.19 ± 9.57 HCC:51.69 ± 10.43 hc: 37.26 ± 10.79 |
Serum | microRNA-101 | RT-qPCR | sensitivity/specificity/ AUC/Cut-off |
| 57 | El-Garem | 2014 | Egypt | case control study | HCC:30(25/5) LC:30(21/9) CH:30(22/8) hc:10(6/4) |
LC/ CH/ hc |
HCC:60.27 ± 8.20 LC:55.07 ± 7.35 CH:38.20 ± 8.21 hc:40.89 ± 16.85 |
Serum | miR-221 | RT-qPCR | sensitivity/specificity/ AUC |
| 58 | Wahb | 2021 | Egypt | case control study | HCC:35(30/5) CH:33(23/10) hc:32(27/5) |
CH/ hc |
HCC:55.2 ± 5.2 CH:52.7 ± 5.3 hc:52.8 ± 5.6 |
Serum | miRNA 9-3p | RT-qPCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off |
| 59 | Youssef | 2022 | Egypt | cohort study | HCC:70(48/22) hc:25 |
hc | HCC:62.0 ± 7.6 | plasma | microRNA-326/microRNA-424/microRNA-511 | qRT-PCR | sensitivity/specificity/ PPV/NPV/AUROC/cut-off/accuracy |
| 60 | Nomair | 2020 | Egypt | N/A | HCC:24(15/9) LC:24(14/10) hc:24(15/9) |
LC/ hc |
HCC: 56.4 ± 7.9 LC: 55.5 ± 6.5 hc: 54.4 ± 5.3 |
Serum | miRNA-224 | RT-PCR | sensitivity/specificity/ AUC/cut-off/accuracy |
| 61 | Moshiri | 2018 | Italy | case-control study | HCC:24 LC:14 |
LC | N/A | Serum | miR-101-3p/miR-106b-3p | N/A | sensitivity/specificity/ AUC/accuracy |
| 62 | Lou | 2022 | China | N/A | HCC:61(50/11) LC:20(14/6) hc:20(13/7) |
LC/ hc |
HCC:55.96 ± 12.34 LC:55.31 ± 12.28 hc:41.65 ± 9.90 |
Serum | lncrna HOTAIR/BRM/ICR | qRT-PCR | sensitivity/specificity/ AUC/cut-off |
| 63 | Farag | 2018 | Saudi Arabia | case-control study | HCC:145(138/7)) CLC:105(70/35) |
CLC | N/A | Serum | GP73mRNA | RT-qPCR | sensitivity/specificity/ PPV/NPV/AUC/accuracy/cut-off |
| 64 | Shehab-Eldeen | 2019 | Egypt | cross-sectional study | HCC: 20(16/4) LC: 20(13/7) hc: 20(10/10) |
LC/ hc |
HCC: 56.95± 1.73 LC: 56.50± 2.1 hc: 52.35± 1.4 |
Serum | microRNA-122/microRNA-224 | RT-qPCR | sensitivity/specificity/ PPV/NPV/AUC/accuracy/cut-off |
| 65 | Aboelwafa | 2021 | Egypt | N/A | LC:100(79/21) HCC:50(40/10) hc:50(35/15) |
LC/ hc |
LC: 47.4 ± 9.7 HCC: 50.6 ± 5.2 hc: 47.5 ± 9.3 |
Serum | miR-23b-3p/miR-331-3p | qRT-PCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off |
| 66 | Cimentepe | 2021 | Turkey | N/A | HCC:35(30/5) CHB:35(16/19) hc:30(17/13) |
CHB/ hc |
HCC:64.7 CHB:35 hc:38 |
Serum | miR-21-5p/miR-122a-5p/miR-221-5p/miR-223-5p | qRT-PCR | AUC |
| 67 | Farag | 2018 | Saudi Arabia | case-control study | HCC:145(138/7) LC:105(75/30) |
LC | N/A | Serum | Glypican-3mRNA | RT-PCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off |
| 68 | Gibriela | 2022 | Egypt | N/A | HCC:40 CLD:48 LC:39 hc:40 |
CLD/ LC/ hc |
N/A | plasma | miR-650/552-3p/676-3p/512-5p/147b | qRT-PCR | sensitivity/specificity/AUC/cut-off |
| 69 | Hussein | 2022 | Egypt | prospective case control study | LC:25 HCC:25 hc:10 |
LC/ hc |
LC:63.44 ± 9 HCC:61 ± 7.76 |
Serum | MicroRNA 21 | RT-PCR | sensitivity/specificity/ AUC/cut-off |
| 70 | Shehab-Eldeen | 2023 | Egypt | case control study | HCC:50(41/9) LC:50(36/14) hc:50(31/19) |
LC/ hc |
HCC: 58.9 ± 5.5 LC: 57.2 ± 7 hc: 59.7 ± 4 |
Serum | MicroRNA-29a/MicroRNA-124 | RT-qPCR | sensitivity/specificity/ PPV/NPV/AUC/cut-off |
| 71 | Xu | 2018 | China | N/A | HCC:100(74/26) LC:100(74/26) CH:100(74/26) hc:100(74/26) |
LC/ CH/ hc |
HCC:54.9 ± 13.1 LC:55.9 ± 12.0 CH:55.6 ± 11.7 hc:54.1 ± 13.8 |
Serum | microRNA-125b | RT-qPCR | sensitivity/specificity/ AUC/cut-off |
| 72 | Zuo | 2014 | China | N/A | HCC:65(48/17) hc:30(17/13) |
hc | Age range: HCC:27-79 hc: 24-80 |
Serum | miR-125b | RT-qPCR | sensitivity/specificity/ AUC/cut-off |
| 73 | Song | 2020 | China | case control study | HCC:94(63/31) CH:52(31/21 |
CH | Age range;median;>60;<60(numbers) HCC:32-75;61;51/43 CH:41-74;62;28/24 |
Serum | lncRNA-PVT1 | qRT-PCR | sensitivity/specificity/ AUC/cut-off |
| 74 | Lyu | 2021 | China | N/A | HCC:111(89/22) LC:58(43/15) CHB:50(35/15) hc:54(36/18) |
LC/ CHB/ hc |
<50;>50(numbers) HCC:31/80 LC:16/42 CHB:17/35 hc:22/32 |
Plasma | hsa circ 0070396 | qRT-PCR | sensitivity/specificity/ AUC |
| 75 | Wang | 2018 | China | N/A | HCC: 50(40/10) LC: 40(25/15) CH: 40(31/9) hc: 50(37/13) |
LC/ CH/ hc |
HCC: 56.32 ± 9.71 LC: 55.13 ± 11.94 CH: 51.25 ± 8.46 hc: 53.92 ± 8.17 |
Serum | Exosomal miR-122/miR-148a/miR-1246 | RT-qPCR | sensitivity/specificity/ AUC |
| 76 | Wang | 2021 | China | N/A | HCC:56(45/11) CHB:57(38/19) LC:47(35/12) |
CHB/ LC |
N/A | Serum | hsa_circ_0028861 | qRT-PCR | sensitivity/specificity/ AUC |
| 77 | Wei | 2022 | China | case control study | HCC:90 hc:90(50/40) |
hc | N/A | Serum | microRNA-370-3p/microRNA-196a-5p | sensitivity/specificity/ AUC |
|
| 78 | Chen | 2022 | China | N/A | HCC:60 hc:60 |
hc | N/A | Serum | miR-34a | qRT-PCR | sensitivity/specificity/ AUC |
| 79 | Ghosh | 2020 | India | N/A | LC:25 HCC:38 CH:35 |
LC/ CH |
N/A | Serum | miR-10b-5p/miR-223-3p/miR-221-3p/miR-21-5p | qRT-PCR | sensitivity/specificity/ AUC |
| 80 | Xu | 2018 | China | N/A | HCC:55 CHB:60 hc:60 |
CHB/ hc |
N/A | Serum | lncRNA ENSG00000258332.1/LINC00635 | qRT-PCR | sensitivity/specificity/ AUC/cut-off |
| 81 | Xu | 2017 | China | N/A | HCC: 88 LC:67 CHB:68 hc:68 |
LC/ CHB/ hc |
N/A | Serum | hnRNPH1 mRNA | qRT-PCR | sensitivity/specificity/ AUC/cut-off |
| 82 | Yang | 2022 | China | N/A | HCC: 50(30/20) LC: 50(29/21) hc: 50(26/24) |
LC/ hc |
HCC: 60.8 ± 5.3 LC: 63.0 ± 3.4 hc: 61.5 ± 5.2 |
exosomes/Plasma | microRNA-26a/microRNA-29c/microRNA199a | qRT-PCR | sensitivity/specificity/ AUC |
BLD, benign liver disease; CH, Chronic hepatitis; CHB, chronic hepatitis B; CHC, chronic hepatitis C; CLD, Cholestatic Liver Disease; DN, Dysplasia of nodules; HCC, Hepatocellular carcinoma; hc, healthy control; LC, Liver cirrhosis; NAFLD, non-alcoholic fatty liver disease, N/A, Not Applicable.